Pradaxa 75 mg, 110 mg, 150 mg Capsule
PDF Leaflet Revision Date: 28 February 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Prevention of venous thromboembolism and stroke reduction in atrial fibrillation.
Dosage (summary)
220 mg once daily for VTE prevention; 300 mg daily for atrial fibrillation.
Onset of Action / Duration
Onset: 1-4 hours, Duration: 12-14 hours
Special Populations
- Renal impairment
- Elderly
Pregnancy & Breastfeeding
Safety not established in pregnancy and lactation.
Key Drug Interactions
- Strong P-glycoprotein inhibitors
- Antiplatelet agents
Contraindications
- Severe renal impairment
- Active bleeding
- Hypersensitivity
Common side effects
- Bleeding
- Gastrointestinal upset
- Anaemia
Counselling Points
- Take with water
- Do not open capsules
- Report any bleeding
Serious warnings
- Increased risk of bleeding
- Monitor renal function
Important Disclaimer
The Pradaxa 75 mg, 110 mg, 150 mg Capsule professional information leaflet below is the property of Ingelheim Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
